Aridis Pharmaceuticals, Inc.
5941 Optical Court
San Jose
California
95138
United States
Tel: 408-385-1742
Fax: 408-960-3822
Website: http://www.aridispharma.com/
74 articles with Aridis Pharmaceuticals, Inc.
-
Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants
2/23/2021
National Institute of Allergy and Infectious Disease (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) are providing preclinical services support to accelerate development
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
-
Aridis' COVID-19 therapy is particularly exciting. AR-711 is an inhaled, self-administered, at-home treatment for mild-to-moderate SARS-CoV-2 infections.
-
Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020
11/24/2020
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute "Fireside Chat Forum," with its five covering analysts will be held on December 4th, 2020 at 11:00AM EST.
-
Aridis Pharmaceuticals Announces Third Quarter 2020 Results
11/20/2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the third quarter ended September 30, 2020.
-
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel
10/27/2020
Aridis Pharmaceuticals, Inc. announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
-
Aridis CEO Confident Inhaled Antibody Formulation Will Play a Key Role in Controlling COVID-19
10/26/2020
Only a fraction of intravenous antibody treatments will make their way to the lungs of COVID-19 patients, which is where the infection is primarily located. Aridis Chief Executive Officer Vu Truong believes his company has a better solution – an inhaled antibody. -
Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients
10/19/2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the development of a highly neutralizing monoclonal antibody AR-711, discovered from convalescent COVID-19 patients, that success
-
Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering
10/14/2020
Aridis Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors with extensive backgrounds in life sciences and biotechnology investing to purchase in a registered direct offering 1,134,470 shares of common stock for $7.4925 per share.
-
Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501
9/8/2020
Aridis Pharmaceuticals, Inc. announced it has reached an agreement with the US Food and Drug Administration to simplify the Company's AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis.
-
Aridis Pharmaceuticals to Present at Upcoming Investor Conferences
9/4/2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong , Ph.D., Chief Executive Officer, will present at the following investor conferences in September:
-
Aridis Pharmaceuticals Announces Second Quarter 2020 Results
8/11/2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the second quarter ended June 30, 2020. Second Quarter Highlights and Recent Developments
-
Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
6/26/2020
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced that Vu Truong, Ph.D., Chief Executive Officer, will participate in Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19" being held on Tuesday, June 30, 2020.
-
Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial
6/22/2020
Phase 1 portion of the Phase 1/2a trial, 48 healthy volunteers were treated with either single or multiple weekly dose regimens
-
Aridis Pharmaceuticals to Discuss APEX™ in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th
6/18/2020
Showcasing the Company's new technology platform geared to rapidly discover new treatments for emerging pulmonary pathogens
-
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
6/15/2020
Aridis Pharmaceuticals, Inc. announced that it has appointed Dr. Hasan Jafri as Chief Medical Officer. Dr. Jafri replaces Dr. Paul Mendelman who has been serving as the Company's interim CMO since October, 2019 and will transition to the role of senior medical advisor to the Company.
-
Aridis Pharmaceuticals Announces First Quarter 2020 Results
5/12/2020
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, reported financial and corporate results for the first quarter ended March 31, 2020.
-
Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP)
5/4/2020
Aridis Pharmaceuticals, Inc. announced the enrollment of its first COVID-19 patient in the Company's ongoing Phase 3 clinical trial of AR-301, a monoclonal antibody against S. aureus induced pneumonia in patients who were already on mechanical ventilators.
-
Aridis Pharmaceuticals to Participate in Maxim Group's Infectious Disease Virtual Conference
4/29/2020
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced its participation in Maxim Group's Infectious Disease Virtual Conference being held on May 5, 2020.